Previously, Simenov et al. demonstrated that the presence of the minor allele led to decreased enhancer activity and IL2RA expression in Jurkat CD4+ T cells.[46] Deletion of the CaRE4 enhancer in mice leads to protection against development of T1D even when the mice are treated with an immunostimulating anti-PD1 checkpoint inhibitor.[47] This provides validation in mice and humans with how the pipeline-identified rs61839660 trio works. Here, CD4 is linked to type 1 diabetes mellitus.